Quantcast

Latest Helsinn Group Stories

2014-07-17 04:20:49

LUGANO, Switzerland and TOKYO, July 17, 2014 /PRNewswire/ -- Under the exclusive agreement, Chugai Pharma Marketing gains rights for the marketing of palonosetron in the UK and NEPA in the UK and in Ireland from Helsinn Group, strengthening the existing alliance between the companies in therapeutic area of supportive cancer care. Helsinn, the Swiss Group focused on building quality cancer care, and Chugai Pharmaceutical Co., Ltd. today announced that exclusive rights to...

2014-07-10 08:27:07

LUGANO, Switzerland, July 10, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, today announces that the complete results of the three Phase 2/3 pivotal trials for the investigational oral fixed-dose combination capsule of netupitant 300 mg + oral palonosetron 0.50 mg (NEPA), which is licensed to Eisai Inc. in the United States, have been published, together with an accompanying editorial, in the July issue of Annals of Oncology....

2014-06-30 08:30:01

LUGANO, Switzerland, June 30, 2014 /PRNewswire/ -- Exclusive distribution and licensing agreement signed for the commercialization of Helsinn's compound currently in development for the treatment of cancer anorexia-cachexia syndrome in non-small cell lung cancer (NSCLC) patients Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilac....

2014-06-26 08:27:36

WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, June 26, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed-dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV), will be presented at the International Symposium on Supportive Care in Cancer. The Multinational Association of Supportive Care in...

2014-06-25 08:32:45

LUGANO, Switzerland, June 25, 2014 /PRNewswire/ -- Helsinn Group, the Company focused on building quality cancer care, announced today the appointment of Dr. Philip S. Schein, to the Board of Directors of its U.S. subsidiary, Helsinn Therapeutics Inc. ("HTU"), effective 8 May 2014. Dr. Philip Schein was the former Founder, Chairman and CEO of US Biosciences, Inc., and Chair of the Clinical Investigations Committee of the National Cancer Advisory Board. Dr. Schein has...

2014-05-28 16:26:44

-- Pediatric Patients Aged 1 Month to Less Than 17 Years Now Have A New Option to Help Prevent Acute Chemotherapy-Induced Nausea and Vomiting -- WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, May 28, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI(®) (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly...

2014-03-13 08:29:55

BRIDGEWATER, New Jersey, March 13, 2014 /PRNewswire/ -- Helsinn Group, the company focused on building quality cancer care, is pleased to announce today that its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc., has been named as one of the 100 best places to work in New Jersey in a survey and award program conducted by NJBIZ which recognizes and honors the state's top employers who show a dedication to their employees' growth and quality of life. In 2009 Helsinn...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related